关键词：肠易激综合征；消化系统；炎性肠疾病
摘 要：Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract , is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Linzess.

04.1.2 Irribow/Irribow OD

04.1.3 Lotronex

04.1.4 Amitiza

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Market Segmentation by Mechanism of

Action

08.1 5HT3 Antagonist

08.2 Guanylate Cyclase Receptor-C Agonist

08.3 Chloride Channel Activator

08.4 Others

09. Market Segmentation by Dosage Form

09.1 Solid

09.2 Liquid

10. Market Segmentation by Indication of

Therapy

10.1 IBS-C

10.2 IBS-D

11. Market Segmentation by End-user Gender23

11.1 Female

11.2 Both

12. Geographical Segmentation

13. Rate of Incidence and Prevalence

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.1.2 Mergers and Acquisitions

21.2 Market Share Analysis 2014

21.2.1 Actavis

21.2.2 Astellas Pharma

21.2.3 Nestlé

21.2.4 Takeda Pharmaceuticals

21.3 Other and Future Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

23.1 Actavis

23.1.1 Key Facts

23.1.2 Business Description

23.1.3 Business Segmentation

23.1.4 Business Segmentation by Revenue 2012 and 2013

23.1.5 Revenue by Geographical Segmentation

23.1.6 Business Strategy

23.1.7 Key Information

23.1.8 SWOT Analysis

23.2 Astellas Pharma

23.2.1 Key Facts

23.2.2 Business Overview

23.2.3 Product Segmentation

23.2.4 Product Segmentation by Revenue 2012 and 2013

23.2.5 Geographical Segmentation by Revenue

23.2.6 Business Strategy

23.2.7 Recent Developments

23.2.8 SWOT Analysis

23.3 Nestlé

23.3.1 Key Facts

23.3.2 Business Overview

23.3.3 Business Segmentation by Revenue 2013

23.3.4 Business Segmentation by Revenue 2012 and 2013

23.3.5 Geographical Segmentation by Revenue 2013

23.3.6 Business Strategy

23.3.7 Recent Developments

23.3.8 SWOT Analysis

23.4 Takeda Pharmaceuticals

23.4.1 Key Facts

23.4.2 Business Overview

23.4.3 Business Segmentation by Revenue 2013

23.4.4 Business Segmentation by Revenue 2013

23.4.5 Geographical Segmentation by Revenue 2013

23.4.6 Business Strategy

23.4.7 Recent Developments

23.4.8 SWOT Analysis

24. Other Reports in this Series